Top

European Archives of Oto-Rhino-Laryngology

Published in:

01-05-2013 | Review Article

Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma

Authors: Antoine Digonnet, Marc Hamoir, Guy Andry, Missak Haigentz Jr., Robert P. Takes, Carl E. Silver, Dana M. Hartl, Primož Strojan, Alessandra Rinaldo, Remco de Bree, Andreas Dietz, Vincent Grégoire, Vinidh Paleri, Johannes A. Langendijk, Vincent Vander Poorten, Michael L. Hinni, Juan P. Rodrigo, Carlos Suárez, William M. Mendenhall, Jochen A. Werner, Eric M. Genden, Alfio Ferlito

Published in: European Archives of Oto-Rhino-Laryngology | Issue 5/2013

Abstract

The management of head and neck squamous cell carcinomas does not end with the completion of ablative therapy. The oncologic objectives of post-treatment follow-up are to detect recurrences and second primary tumors; beyond that, follow-up should evaluate acute and chronic treatment-related side effects, guide the rehabilitation process, alleviate functional loss, manage pain, restore nutritional status and assess psychosocial factors. In this structured review, we address the questions of timing and the tools required to achieve a complete and coherent routine surveillance. Several guidelines and consensus statements recommend clinical examination as the cornerstone of follow-up which should be performed for at least 5 years, although there are no data in favor of any one particular follow-up program, and only low-level evidence suggests an improvement in oncologic outcomes by close follow-up. Baseline imaging (computed tomography and magnetic resonance imaging) should be obtained within 2–6 months after definitive therapy if used for treatment response evaluation. Metabolic response, if indicated, should be assessed preferably after 3 months in patients who undergo curative-intent therapy with (chemo)-radiotherapy. Chest computed tomography is more sensitive than plain radiography, if used in follow-up, but the benefit and cost-effectiveness of routine chest computed tomography has not been demonstrated. There are no current data supporting modifications specific to the surveillance plan of patients with human papillomavirus-associated disease.

Cooney TR, Poulsen MG (1999) Is routine follow-up useful after combined-modality therapy for advanced head and neck cancer? Arch Otolaryngol Head Neck Surg 125:379–382PubMed

Virgo KS, Paniello RC, Johnson FE (1998) Costs of posttreatment surveillance for patients with upper aerodigestive tract cancer. Arch Otolaryngol Head Neck Surg 124:564–572PubMed

Boysen M, Lövdal O, Tausjö J, Winther F (1992) The value of follow-up in patients treated for squamous cell carcinoma of the head and neck. Eur J Cancer 28:426–430CrossRefPubMed

de Visscher AV, Manni JJ (1994) Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity. Does it make sense? Arch Otolaryngol Head Neck Surg 120:934–939CrossRefPubMed

Lester SE, Wight RG (2009) ‘When will I see you again?’ Using local recurrence data to develop a regimen for routine surveillance in post-treatment head and neck cancer patients. Clin Otolaryngol 34:546–551CrossRefPubMed

Wensing BM, Merkx MA, Krabbe PF, Marres HA, Van den Hoogen FJ (2011) Oral squamous cell carcinoma and a clinically negative neck: the value of follow-up. Head Neck 33:1400–1405CrossRefPubMed

Ridge JA (1993) Squamous cancer of the head and neck: surgical treatment of local and regional recurrence. Semin Oncol 20:419–429PubMed

Haigentz M Jr, Hartl DM, Silver CE et al (2012) Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment. Oral Oncol 48:787–793

Kurzweg T, Möckelmann N, Laban S, Knecht R (2012) Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year’s literature. Eur Arch Otorhinolaryngol [Epub ahead of print]

10.

Balermpas P, Keller C, Hambek M et al (2012) Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. Int J Radiat Oncol Biol Phys 83:e377–e383

11.

Tan IB, Dolivet G, Ceruse P, Vander Poorten V, Roest G, Rauschning W (2010) Temoporfin-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study. Head Neck 2:1597–1604

12.

Schwartz LH, Ozsahin M, Zhang GN et al (1994) Synchronous and metachronous head and neck carcinomas. Cancer 74:1933–1938CrossRefPubMed

13.

Sturgis EM, Miller RH (1995) Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol 104:946–954PubMed

14.

Kaanders JH, Dutch Cooperative Head and Neck Oncology Group (2002) Carcinoma of the larynx: the Dutch national guideline for diagnostics, treatment, supportive care and rehabilitation. Radiother Oncol 63:299–307CrossRefPubMed

15.

Johnson F, Johnson M, Virgo K (1997) Current follow-up strategies after potentially curative resection of upper aerodigestive tract epidermoid carcinoma. Int J Oncol 10:927–931PubMed

16.

Paniello RC, Virgo KS, Johnson MH, Clemente MF, Johnson FE (1999) Practice patterns and clinical guidelines for posttreatment follow-up of head and neck cancers: a comparison of 2 professional societies. Arch Otolaryngol Head Neck Surg 125:309–313PubMed

17.

Andl T, Kahn T, Pfuhl A et al (1998) Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58:5–13PubMed

18.

Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35CrossRefPubMed

19.

Manikantan K, Khode S, Dwivedi RC et al (2009) Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev 35:744–753CrossRefPubMed

20.

Flynn CJ, Khaouam N, Gardner S et al (2010) The value of periodic follow-up in the detection of recurrences after radical treatment in locally advanced head and neck cancer. Clin Oncol (R Coll Radiol) 22:868–873CrossRef

21.

Merkx MA, van Gulick JJ, Marres HA et al (2006) Effectiveness of routine follow-up of patients treated for T1-2N0 oral squamous cell carcinomas of the floor of mouth and tongue. Head Neck 28:1–7CrossRefPubMed

22.

Ritoe SC, Krabbe PF, Kaanders JH, van den Hoogen FJ, Verbeek AL, Marres HA (2004) Value of routine follow-up for patients cured of laryngeal carcinoma. Cancer 101:1382–1389CrossRefPubMed

23.

Ritoe SC, Verbeek AL, Krabbe PF, Kaanders JH, van den Hoogen FJ, Marres HA (2007) Screening for local and regional cancer recurrence in patients curatively treated for laryngeal cancer: definition of a high-risk group and estimation of the lead time. Head Neck 29:431–438CrossRefPubMed

24.

Kissun D, Magennis P, Lowe D, Brown JS, Vaughan ED, Rogers SN (2006) Timing and presentation of recurrent oral and oropharyngeal squamous cell carcinoma and awareness in the outpatient clinic. Br J Oral Maxillofac Surg 44:371–376CrossRefPubMed

25.

Johnson FE, Johnson MH, Clemente MF, Paniello RC, Virgo KS (2006) Geographical variation in surveillance strategies after curative-intent surgery for upper aerodigestive tract cancer. Ann Surg Oncol 13:1063–1071CrossRefPubMed

26.

Kazi R, Manikanthan K, Pathak KA, Dwivedi RC (2010) Head and neck squamous cell cancers: need for an organised time-bound surveillance plan. Eur Arch Otorhinolaryngol 267:1969–1971CrossRefPubMed

27.

British Association of Head and Neck Oncologists (2001) Practice care guidance for clinicians participating in the management of head and neck cancer patients in the UK. Drawn up by a consensus group of practising clinicians. Practice care guidance for clinicians participating in the management of head and neck cancer patients in the UK. EJSO 27(Suppl A):S1–S17

28.

Pfister DG, Ang KK, Brizel DM et al (2011) National Comprehensive Cancer Network clinical practice guidelines in oncology. Head and neck cancers. J Natl Compr Canc Netw 9:596–650PubMed

29.

Johnson FE, Virgo KS, Clemente MF, Johnson MH, Paniello RC (1998) How tumor stage affects surgeons’ surveillance strategies after surgery for carcinoma of the upper aerodigestive tract. Cancer 82:1932–1937CrossRefPubMed

30.

Coca-Pelaz A, Rodrigo JP, Suárez C (2012) Clinicopathologic analysis and predictive factors for distant metastases in patients with head and neck squamous cell carcinomas. Head Neck 34:771–775CrossRefPubMed

31.

de Bree R, Haigentz M Jr, Silver CE et al (2012) Distant metastases from head and neck squamous cell carcinoma. Part II. Diagnosis. Oral Oncol 48:780–786

32.

Daisne JF, Duprez T, Weynand B et al (2004) Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233:93–100CrossRefPubMed

33.

Manikantan K, Dwivedi RC, Sayed SI, Pathak KA, Kazi R (2011) Current concepts of surveillance and its significance in head and neck cancer. Ann R Coll Surg Engl 93:576–582CrossRefPubMed

34.

Chu PY, Tsai TL, Tai SK, Chang SY (2012) Effectiveness of narrow band imaging in patients with oral squamous cell carcinoma after treatment. Head Neck 34:155–161CrossRefPubMed

35.

Piazza C, Cocco D, De Benedetto L, Bon FD, Nicolai P, Peretti G (2010) Role of narrow-band imaging and high-definition television in the surveillance of head and neck squamous cell cancer after chemo- and/or radiotherapy. Eur Arch Otorhinolaryngol 267:1423–1428CrossRefPubMed

36.

Rydell R, Eker C, Andersson-Engels S, Krogdahl A, Wahlberg P, Svanberg K (2008) Fluorescence investigations to classify malignant laryngeal lesions in vivo. Head Neck 30:419–426CrossRefPubMed

37.

Tschiesner U, Rogers S, Dietz A, Yueh B, Cieza A (2010) Development of ICF core sets for head and neck cancer. Head Neck 32:210–220PubMed

38.

Leib A, Cieza A, Tschiesner U (2012) Perspective of physicians within a multidisciplinary team: content validation of the comprehensive ICF core set for head and neck cancer. Head Neck 34:956–966

39.

Schuurhuis JM, Stokman MA, Roodenburg JL et al (2011) Efficacy of routine pre-radiation dental screening and dental follow-up in head and neck oncology patients on intermediate and late radiation effects. A retrospective evaluation. Radiother Oncol 101:403–409CrossRefPubMed

40.

Tolentino Ede S, Centurion BS, Ferreira LH, Souza AP, Damante JH, Rubira-Bullen IR (2011) Oral adverse effects of head and neck radiotherapy: literature review and suggestion of a clinical oral care guideline for irradiated patients. J Appl Oral Sci 19:448–454

41.

Ho KF, Farnell DJ, Routledge JA et al (2009) Developing a CTCAEs patient questionnaire for late toxicity after head and neck radiotherapy. Eur J Cancer 45:1992–1998CrossRefPubMed

42.

Stoeckli SJ, Zimmermann R, Schmid S (2001) Role of routine panendoscopy in cancer of the upper aerodigestive tract. Otolaryngol Head Neck Surg 124:208–212CrossRefPubMed

43.

Rachmat L, Vreeburg GC, de Vries N et al (1993) The value of twice yearly bronchoscopy in the work-up and follow-up of patients with laryngeal cancer. Eur J Cancer 29A:1096–1099CrossRefPubMed

44.

Haughey BH, Gates GA, Arfken CL, Harvey J (1992) Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Ann Otol Rhinol Laryngol 101:105–112PubMed

45.

Lee P, de Bree R, Brokx HA, Leemans CR, Postmus PE, Sutedja TG (2008) Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: is there a role for autofluorescence bronchoscopy? Lung Cancer 62:309–315CrossRefPubMed

46.

Bakhshandeh M, Hashemi B, Mahdavi SR, Nikoofar A, Vasheghani M, Kazemnejad A (2012) Normal tissue complication probability modeling of radiation-induced hypothyroidism after head-and-neck radiation therapy. Int J Radiat Oncol Biol Phys [Epub ahead of print]

47.

Vogelius IR, Bentzen SM, Maraldo MV, Petersen PM, Specht L (2011) Risk factors for radiation-induced hypothyroidism. Cancer 117:5250–5260CrossRefPubMed

48.

Sinard RJ, Tobin EJ, Mazzaferri EL et al (2000) Hypothyroidism after treatment for nonthyroid head and neck cancer. Arch Otolaryngol Head Neck Surg 126:652–657PubMed

49.

Jereczek-Fossa BA, Alterio D, Jassem J, Gibelli B, Tradati N, Orecchia R (2004) Radiotherapy-induced thyroid disorders. Cancer Treat Rev 30:369–384CrossRefPubMed

50.

Garcia-Serra A, Amdur RJ, Morris CG, Mazzaferri E, Mendenhall WM (2005) Thyroid function should be monitored following radiotherapy to the low neck. Am J Clin Oncol 28:255–258CrossRefPubMed

51.

Hermans R, Pameijer FA, Mancuso AA, Parsons JT, Mendenhall WM (2000) Laryngeal or hypopharyngeal squamous cell carcinoma: can follow-up CT after definitive radiation therapy be used to detect local failure earlier than clinical examination alone? Radiology 214:683–687PubMed

52.

Wang J, Takashima S, Takayama F et al (2001) Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology 220:621–630CrossRefPubMed

53.

Vandecaveye V, De Keyzer F, Nuyts S et al (2007) Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys 67:960–971CrossRefPubMed

54.

Vandecaveye V, Dirix P, De Keyzer F et al (2012) Diffusion-weighted magnetic resonance imaging early after chemoradiotherapy to monitor treatment response in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 82:1098–1107CrossRefPubMed

55.

León X, Quer M, Orús C, del Prado Venegas M, López M (2000) Distant metastases in head and neck cancer patients who achieved loco-regional control. Head Neck 22:680–686

56.

Ferlito A, Shaha AR, Rinaldo A, Pellitteri PK, Mondin V, Byers RM (2002) “Skip metastases” from head and neck cancers. Acta Otolaryngol 122:788–791CrossRefPubMed

57.

Engelen AM, Stalpers LJ, Manni JJ, Ruijs JH, van Daal WA (1992) Yearly chest radiography in the early detection of lung cancer following laryngeal cancer. Eur Arch Otorhinolaryngol 249:364–369CrossRefPubMed

58.

Warner GC, Cox GJ (2003) Evaluation of chest radiography versus chest computed tomography in screening for pulmonary malignancy in advanced head and neck cancer. J Otolaryngol 32:107–109CrossRefPubMed

59.

Glynn F, Brennan S, O’Leary G (2006) CT staging and surveillance of the thorax in patients with newly diagnosed and recurrent squamous cell carcinoma of the head and neck: is it necessary? Eur Arch Otorhinolaryngol 263:943–945CrossRefPubMed

60.

Loh KS, Brown DH, Baker JT, Gilbert RW, Gullane PJ, Irish JC (2005) A rational approach to pulmonary screening in newly diagnosed head and neck cancer. Head Neck 27:990–994CrossRefPubMed

61.

Hsu YB, Chu PY, Liu JC et al (2008) Role of chest computed tomography in head and neck cancer. Arch Otolaryngol Head Neck Surg 134:1050–1054CrossRefPubMed

62.

Ritoe SC, Krabbe PF, Jansen MM et al (2002) Screening for second primary lung cancer after treatment of laryngeal cancer. Laryngoscope 112:2002–2008CrossRefPubMed

63.

Buwalda J, Zuur CL, Lubsen H, Tijssen JG, Koole R, Hordijk GJ (1999) Annual chest X-ray in patients after treatment for laryngeal or oral cancer: only a limited number of second primary lung cancers detected. Ned Tijdschr Geneeskd 143:1517–1522 (Article in Dutch)

64.

Di Martino E, Nowak B, Hassan HA et al (2000) Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. Arch Otolaryngol Head Neck Surg 126:1457–1461PubMed

65.

Yoon DY, Hwang HS, Chang SK et al (2009) CT, MR, US, ¹⁸F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol 19:634–642CrossRefPubMed

66.

Adams S, Baum RP, Stuckensen T, Bitter K, Hör G (1998) Prospective comparison of ¹⁸F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25:1255–1260CrossRefPubMed

67.

Leuwer RM, Westhofen M, Schade G (1997) Color duplex echography in head and neck cancer. Am J Otolaryngol 18:254–257CrossRefPubMed

68.

van der Putten L, van den Broek GB, de Bree R et al (2009) Effectiveness of salvage selective and modified radical neck dissection for regional pathologic lymphadenopathy after chemoradiation. Head Neck 31:593–603CrossRefPubMed

69.

Park JJ, Emmerling O, Westhofen M (2012) Role of neck ultrasound during follow-up care of head and neck squamous cell carcinomas. Acta Otolaryngol 132:218–224CrossRefPubMed

70.

Nieuwenhuis EJ, Castelijns JA, Pijpers R et al (2002) Wait-and-see policy for the N0 neck in early-stage oral and oropharyngeal squamous cell carcinoma using ultrasonography-guided cytology: is there a role for identification of the sentinel node? Head Neck 24:282–289CrossRefPubMed

71.

Smith GL, Smith BD, Buchholz TA et al (2008) Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol 26:5119–5125CrossRefPubMed

72.

Qureshi AI, Alexandrov AV, Tegeler CH et al (2007) Guidelines for screening of extracranial carotid artery disease: a statement for healthcare professionals from the multidisciplinary practice guidelines committee of the American Society of Neuroimaging; cosponsored by the Society of Vascular and Interventional Neurology. J Neuroimaging 17:19–47CrossRefPubMed

73.

Zimmer LA, Branstetter BF, Nayak JV, Johnson JT (2005) Current use of ¹⁸F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope 115:2029–2034CrossRefPubMed

74.

Schöder H, Fury M, Lee N, Kraus D (2009) PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 50(Suppl 1):74S–88SCrossRefPubMed

75.

Connell CA, Corry J, Milner AD et al (2007) Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 29:986–995CrossRefPubMed

76.

Abgral R, Querellou S, Potard G et al (2009) Does ¹⁸F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 50:24–29CrossRefPubMed

77.

Stokkel MP, Terhaard CH, Hordijk GJ, van Rijk PP (1999) The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography. Eur J Nucl Med 26:767–773CrossRefPubMed

78.

Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ (2001) F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck 23:933–941CrossRefPubMed

79.

Gupta T, Master Z, Kannan S et al (2011) Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 38:2083–2095CrossRefPubMed

80.

Fukui MB, Blodgett TM, Meltzer CC (2003) PET/CT imaging in recurrent head and neck cancer. Semin Ultrasound CT MR 24:157–163CrossRefPubMed

81.

Porceddu SV, Jarmolowski E, Hicks RJ et al (2005) Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 27:175–181CrossRefPubMed

82.

Yao M, Smith RB, Graham MM et al (2005) The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 63:991–999CrossRefPubMed

83.

Haerle SK, Schmid DT, Ahmad N, Hany TF, Stoeckli SJ (2011) The value of ¹⁸F-FDG PET-CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma. Oral Oncol 47:653–659CrossRefPubMed

84.

de Bree R, van der Putten L, Brouwer J, Castelijns JA, Hoekstra OS, Leemans CR (2009) Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging. Oral Oncol 45:386–393CrossRefPubMed

85.

Lee JC, Kim JS, Lee JH et al (2007) F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma. Oral Oncol 43:686–692CrossRefPubMed

86.

Wong RJ (2008) Current status of FDG-PET for head and neck cancer. J Surg Oncol 97:649–652CrossRefPubMed

87.

D’Souza G, Kreimer AR, Viscidi R et al (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944–1956CrossRefPubMed

88.

Licitra L, Perrone F, Bossi P et al (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630–5636CrossRefPubMed

89.

Hafkamp HC, Manni JJ, Haesevoets A et al (2008) Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 122:2656–2664CrossRefPubMed

90.

Lewis JS Jr, Thorstad WL, Chernock RD et al (2010) p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 34:1088–1096CrossRefPubMed

Title: Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma
Authors: Antoine Digonnet
Marc Hamoir
Guy Andry
Missak Haigentz Jr.
Robert P. Takes
Carl E. Silver
Dana M. Hartl
Primož Strojan
Alessandra Rinaldo
Remco de Bree
Andreas Dietz
Vincent Grégoire
Vinidh Paleri
Johannes A. Langendijk
Vincent Vander Poorten
Michael L. Hinni
Juan P. Rodrigo
Carlos Suárez
William M. Mendenhall
Jochen A. Werner
Eric M. Genden
Alfio Ferlito
Publication date: 01-05-2013
Publisher: Springer-Verlag
Published in: European Archives of Oto-Rhino-Laryngology / Issue 5/2013
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-012-2172-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Change of prevalence and clinical aspects of fungal ball according to temporal difference

Endoscopic laser medial arytenoidectomy for treatment of bilateral vocal fold paralysis

To nasendoscope or not to nasendoscope, that is the question

Modulation of wireless (2.45 GHz)-induced oxidative toxicity in laryngotracheal mucosa of rat by melatonin

Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study

The misdiagnosis of external auditory canal carcinoma